News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
|Articles|September 17, 2019

PE 2020 Media Kit

External Link - PE_2020_MediaKit_final_r1.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Whitepapers

Related Content

Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: FDA Approves Auvelity

ByNicholas Jacobus
May 1st 2026
Stock.adobe.com clinical trial

FDA’s Oncologic Drugs Advisory Committee Recognizes Favorable Risk Benefit for Truqap

ByNicholas Jacobus
May 1st 2026
Jeff Golfman Send 123

Global Disruptions to the Pharma Supply Chain: Q&A with Jeff Golfman

ByNicholas Jacobus,Jeff Golfman
May 1st 2026
Stock.adobe.com alzheimer's agitation

FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers

ByNicholas Jacobus
May 1st 2026
Will Shrank

Asembia ASX26: Payers and the Rising Costs for Cell & Gene Therapies

ByMike Hollan,Will Shrank
May 1st 2026

Trending on PharmExec

1

Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?

2

Using a Customer-Based Process to Synchronize Sales & Marketing Organizations in Pharma

3

Alternative Supply Chain Strategies Companies Should Prioritize

4

FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers

5

Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us